News & Media

Latest news

FEATURED ARTICLE

News & Media

Cagent Vascular Announces Landmark Peer-Reviewed Data Demonstrating Safety and Efficacy of Serration Remodeling Therapy™ in the Most Challenging Arteries Below-the-Ankle

Jessica Grassi 6/29/26 Jessica Grassi 6/29/26

Cagent Vascular Announces Landmark Peer-Reviewed Data Demonstrating Safety and Efficacy of Serration Remodeling Therapy™ in the Most Challenging Arteries Below-the-Ankle

Meg McConnell 10/7/25 Meg McConnell 10/7/25

Cagent Vascular Expands Serranator Product Line with Launch of 7.0 mm and 8.0 mm Sizes

Meg McConnell 8/5/25 Meg McConnell 8/5/25

WDEF News 12: New Tech from Cagent Vascular brings Serrated Edge to Vascular Care

Meg McConnell 4/10/25 Meg McConnell 4/10/25

Cagent Vascular Initiates Patient Enrollment in the Serranator® vs. POBA OCT Study at Columbia University Medical Center

Meg McConnell 4/3/25 Meg McConnell 4/3/25

Cagent Vascular and 3comma Medical Announce Strategic Partnership to Expand International Distribution of Serranator Product Family in EU and MENA Regions

Meg McConnell 3/4/25 Meg McConnell 3/4/25

Paul Wilson Appointed as Chief Commercial Officer to Drive Growth and Market Expansion

Meg McConnell 2/3/25 Meg McConnell 2/3/25

Cagent Vascular Announces Launch of New Product Serranator SL-PRO for CLTI and Pedal Disease

Meg McConnell 1/28/25 Meg McConnell 1/28/25

Cagent Vascular Initiates the Serranator® POINT FORCE Observational Registry

Meg McConnell 10/3/24 Meg McConnell 10/3/24

It's Time for a New Standard of Care: Addressing PAD with Serration Technology

Meg McConnell 6/11/24 Meg McConnell 6/11/24

Innovation with Serration: Serranator featured in Endovascular Today

Meg McConnell 5/6/24 Meg McConnell 5/6/24

Cagent Vascular appoints Chairman Brian Walsh to expanded role as Chief Executive Officer

Meg McConnell 2/19/24 Meg McConnell 2/19/24

Cagent Vascular Raises $30 Million Series C Financing

Meg McConnell 7/11/23 Meg McConnell 7/11/23

Cagent Vascular announces initial RECOIL Study results

Meg McConnell 6/7/23 Meg McConnell 6/7/23

Study finds Serranator serration balloon safe and effective in pedal arteries

Meg McConnell 5/31/23 Meg McConnell 5/31/23

Endovascular Today: Using Serranator® in Challenging CLTI Cases

Meg McConnell 5/31/23 Meg McConnell 5/31/23

Serranator Featured in Cath Lab Digest

Meg McConnell 1/31/23 Meg McConnell 1/31/23

Superior lumen gain, greater volumetric blood flow using Serranator: A sub-analysis of the PRELUDE BTK Study

Meg McConnell 11/30/21 Meg McConnell 11/30/21

Publication of the PRELUDE-BTK Study

Meg McConnell 6/17/21 Meg McConnell 6/17/21

Sectoral Asset Management Makes $9M Investment into Cagent Vascular

Meg McConnell 2/1/21 Meg McConnell 2/1/21

Cagent Vascular Announces PRELUDE-BTK Study Results Presented at LINC Symposium: Confirms Serranator Device Novel Mechanism of Action

Latest news

Cagent Vascular Announces Landmark Peer-Reviewed Data Demonstrating Safety and Efficacy of Serration Remodeling Therapy™ in the Most Challenging Arteries Below-the-Ankle

Cagent Vascular Expands Serranator Product Line with Launch of 7.0 mm and 8.0 mm Sizes

WDEF News 12: New Tech from Cagent Vascular brings Serrated Edge to Vascular Care

Cagent Vascular Initiates Patient Enrollment in the Serranator® vs. POBA OCT Study at Columbia University Medical Center

Cagent Vascular and 3comma Medical Announce Strategic Partnership to Expand International Distribution of Serranator Product Family in EU and MENA Regions

Paul Wilson Appointed as Chief Commercial Officer to Drive Growth and Market Expansion

Cagent Vascular Announces Launch of New Product Serranator SL-PRO for CLTI and Pedal Disease

Cagent Vascular Initiates the Serranator® POINT FORCE Observational Registry

It's Time for a New Standard of Care: Addressing PAD with Serration Technology

Innovation with Serration: Serranator featured in Endovascular Today

Cagent Vascular appoints Chairman Brian Walsh to expanded role as Chief Executive Officer

Cagent Vascular Raises $30 Million Series C Financing

Cagent Vascular announces initial RECOIL Study results

Study finds Serranator serration balloon safe and effective in pedal arteries

Endovascular Today: Using Serranator® in Challenging CLTI Cases

Serranator Featured in Cath Lab Digest

Superior lumen gain, greater volumetric blood flow using Serranator: A sub-analysis of the PRELUDE BTK Study

Publication of the PRELUDE-BTK Study

Sectoral Asset Management Makes $9M Investment into Cagent Vascular

Cagent Vascular Announces PRELUDE-BTK Study Results Presented at LINC Symposium: Confirms Serranator Device Novel Mechanism of Action

PRODUCTS

RESOURCES

SOLUTIONS

COMPANY

PATIENTS

Contact

Stay in the Know